Montoya, AlonsoQuail, DeborahAnand, ErnieCardo-Jalon, EstherAlda, Jose AEscobar, Rodrigo2024-07-032024-07-032014Montoya Alonso, Quail Deborah, Anand Ernie, Cardo Esther, Alda Jose A, Escobar Rodrigo. Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.. Atten Defic Hyperact Disord. 2014;6(1):25-34. Epub 2013 Oct 20.1866-6647http://hdl.handle.net/20.500.13003/17105http://hdl.handle.net/20.500.12105/19942The objective of this study is to identify prognostic factors of treatment response to atomoxetine in improvement of health-related quality of life (HR-QoL), measured by the Child Health and Illness Profile-Child Edition Parent Report Form (CHIP-CE PRF) Achievement and Risk Avoidance domains, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Pooled data from 3 placebo-controlled trials and separate data from 3 open-label trials of atomoxetine in children and adolescents with ADHD were analyzed using logistic regression methods. Based on baseline impairment in the Achievement and/or Risk Avoidance domains (CHIP-CE PRF < 40 points), 2 subsamples of subjects were included. Treatment outcome was categorized as <5 points or ?5 points increase in the CHIP-CE PRF Achievement and Risk Avoidance domains. Data of 190 and 183 subjects from the pooled sample, and 422 and 355 subjects from the open-label trials were included in the analysis of Achievement and Risk Avoidance domains. Baseline CHIP-CE subdomain scores proved to be the most robust prognostic factors for treatment outcome in both domains, based on data from the pooled sample of double-blind studies and from the individual open-label studies (odds ratios [OR] 0.74-1.56, p < 0.05; OR < 1, indicating a worse baseline score associated with worse odds of responding). Initial treatment response (?25 % reduction in ADHD Rating Scale scores in the first 4-6 weeks) was another robust prognostic factor, based on data from the open-label studies (OR 2.99-6.19, p < 0.05). Baseline impairment in HR-QoL and initial treatment response can be early prognostic factors of atomoxetine treatment outcome in HR-QoL in children and adolescents with ADHD.enghttps://creativecommons.org/licenses/by/3.0/ChildClinical Trials as TopicEducational StatusHumansRisk Reduction BehaviorAttention Deficit Disorder with HyperactivityDouble-Blind MethodPrognosisMaleQuality of LifePropylaminesFemaleTreatment OutcomeLogistic Modelsresearch articleAttribution 3.0 Unported241423056125-3410.1007/s12402-013-0119-5Attention Deficit and Hyperactivity Disordersopen accessResultado del TratamientoModelos LogísticosFemeninoConducta de Reducción del RiesgoMasculinoMétodo Doble CiegoTrastorno por Déficit de Atención con HiperactividadPropilaminasHumanosCalidad de VidaEscolaridadPronósticoEnsayos Clínicos como AsuntoNiño2-s2.0-84896893924L372493955